Malaria -stricken countries in Africa have less cause to worry as a vaccine known as R21/Matrix developed by scientists at Oxford University has received approval to be used in Ghana.
The vaccine is said to be 80 percent effective in preventing malaria.
Before the Oxford Vaccine approval,the World Health Organisation (WHO ),had endorsed only the RTS, S/AS01 (RTS,S) vaccine tested to be 29 percent effective in preventing severe malaria.
Oxford University in a statement Thursday said this is the first time its vaccine has received regulatory clearance anywhere in the world.
It said the vaccine which was originally developed in Oxford has undergone clinical trials in other countries and demonstrated high levels of efficacy and safety in phase II trials, including amongst children who received a booster dose of R21/Matrix-M at one year following a primary three-dose regime.
“The vaccine has been approved for use in children aged 5 to 36 months, the age group at highest risk of death from malaria. It is hoped that this first crucial step will enable the vaccine to help Ghanaian and African children to effectively combat malaria,”
“The R21/Matrix-M malaria vaccine is a low-dose vaccine that can be manufactured at mass scale and modest cost, enabling as many as hundreds of millions of doses to be supplied to African countries which are suffering a significant malaria burden.
“The R21/Matrix-M vaccine was initially designed and developed at the University of Oxford and has undergone clinical trials in the UK, Thailand, and several African countries, including an ongoing phase III trial in Burkina Faso, Kenya, Mali and Tanzania that has enrolled 4,800 children. Results from these trials are expected to be reported later this year.”
R21/Matrix-M programme, Chief Investigator, Adrian Hill, said the approval marks the highest point of 30 years of malaria vaccine research at the institution and thanked the partners for a job well done.
“I congratulate our superb clinical trial partners in Africa who have generated the dataset supporting the safety and efficacy of the vaccine in children. As with the Oxford-AstraZeneca COVID-19 vaccine, our partnership with the Serum Institute of India has been key to successful very large – scale manufacturing and rapid development ” he said.
